Visceral Fat: Why It Matters More Than BMI and What a DEXA Scan Can Show

One-Minute Read

Visceral fat is different from the fat you can pinch beneath the skin. It is stored deeper in the abdomen, surrounding organs such as the liver and intestines, and it has a much closer relationship with insulin resistance and cardiometabolic disease.

The difficult part is that visceral fat is not obvious from appearance. Someone can have a normal BMI and still carry more visceral fat than expected, while another person at the same weight may have substantially more muscle and relatively little visceral fat. A bathroom scale cannot tell the difference.

At HormoneSynergy®, this is one reason we use Hologic® DEXA body-composition testing. DEXA provides an imaging-based estimate of visceral adipose tissue while also showing total fat mass, regional fat distribution, lean mass and bone density. We do not interpret the VAT number in isolation. We look at it alongside fasting insulin, HOMA-IR, glucose, triglycerides, ApoB, blood pressure, liver health, muscle mass, hormone changes, sleep, exercise and the rest of the metabolic picture.

The clinical goal is not simply to lose weight. It is to reduce excess visceral fat when present, preserve or build muscle, maintain bone and improve the physiology associated with long-term health.

In This Article

• What visceral fat actually is
• Why visceral fat matters for longevity
• Why BMI can miss the problem
• What DEXA can tell us about visceral fat
• How to interpret a VAT number
• Hormones, menopause and body-fat distribution
• How we approach reducing visceral fat
• How HormoneSynergy® uses DEXA

What Is Visceral Fat?

Body fat is not one uniform tissue compartment.

Subcutaneous fat sits beneath the skin. It accounts for much of the fat that is visible externally and can usually be felt or pinched.

Visceral adipose tissue, usually abbreviated VAT, is stored deeper within the abdominal cavity around and between internal organs.

Visceral adipose tissue is metabolically active. It participates in inflammatory signaling, fatty-acid metabolism and the regulation of several adipokines involved in metabolic function. Higher amounts of VAT are consistently associated with insulin resistance, type 2 diabetes, metabolic-associated steatotic liver disease, abnormal triglyceride metabolism and cardiovascular risk.

This does not mean that visceral fat alone causes every one of these conditions, or that a single VAT measurement establishes someone's future risk. It means that visceral adiposity is a clinically useful marker of the metabolic environment in which these diseases tend to develop.

Why Visceral Fat Matters in Longevity Medicine

In longevity medicine, we are interested in physiologic changes that can be identified before they become established disease. Visceral fat belongs in that conversation because it frequently travels with other early changes in metabolism.

As visceral adiposity rises, we may also see higher fasting insulin, worsening insulin sensitivity, increasing triglycerides, fatty-liver patterns, higher blood pressure or other signs of metabolic strain. Cardiovascular risk may rise as several of these factors begin to cluster together.

We therefore do not think of visceral fat as simply an issue of appearance or body weight. It is part of the same physiology we evaluate when looking at insulin resistance, metabolic syndrome and preventive cardiovascular health.

For a broader discussion, see our Metabolic Health & Insulin Resistance Guide.

Why BMI Can Miss Visceral Fat

BMI is calculated from height and weight. It does not know whether that weight comes from skeletal muscle, subcutaneous fat, visceral fat or bone.

This becomes clinically important when two people with the same BMI have very different body compositions.

A physically active person with substantial lean mass may have a BMI that places them in an overweight category despite having relatively little visceral fat. Another person can have a normal BMI while carrying less muscle and considerably more abdominal fat.

Waist circumference adds useful information and remains a practical screening measurement, but it cannot completely separate subcutaneous abdominal fat from the visceral fat stored deeper inside the abdomen.

What a DEXA Scan Can Tell Us About Visceral Fat

DEXA stands for dual-energy X-ray absorptiometry. Most people know it as a test for bone density, but modern whole-body DEXA systems can provide considerably more information about body composition.

At HormoneSynergy®, we use a Hologic® DEXA system. The body-composition analysis can evaluate total body fat, regional fat distribution, lean tissue and abdominal visceral adipose tissue.

DEXA does not anatomically segment every cubic centimeter of visceral fat in the way a CT or MRI examination can. Its software uses imaging data from the abdominal region to estimate visceral adipose tissue after accounting for the surrounding subcutaneous fat. Validation studies involving Hologic® systems have shown good correlation between DEXA-derived VAT and MRI measurements.

This makes DEXA particularly useful clinically because the same examination also tells us what is happening to muscle, total fat and bone.

A person who loses twenty pounds but also loses a substantial amount of lean mass presents a different clinical picture from someone who loses visceral and total fat while maintaining muscle. The scale may show an identical result, but the physiology is not identical.

Learn more about our Hologic® DEXA Bone Density, Body Composition & Visceral Fat Testing.

What Is a Healthy Visceral Fat Number?

This is where some of the discussion around visceral fat becomes more precise than the science permits.

There is not one universal VAT number that applies to every person, every DEXA manufacturer and every clinical situation. VAT may be reported as area, mass or volume, and values obtained with different scanners and software should not automatically be treated as interchangeable.

A 2025 analysis using U.S. NHANES data identified an overall DEXA-derived VAT volume threshold of approximately 327 cm³ associated with higher cardiovascular disease prevalence. The estimated threshold differed by sex, at approximately 387.5 cm³ for men and 312 cm³ for women.

Those numbers are useful research data, but we would not turn them into a universal treatment target. They came from a population analysis, not from a trial showing that lowering someone from one specific VAT value to another prevents a cardiovascular event.

In practice, we are more interested in three questions:

• Is the visceral-fat measurement consistent with the person's overall metabolic and cardiovascular risk?
• What is happening to skeletal muscle, total fat and other body-composition markers at the same time?
• Is the pattern improving or worsening when it is measured again under comparable conditions?

Serial measurements are most useful when performed on the same system and interpreted with the rest of the clinical picture.

Hormones, Menopause and Visceral Fat

Body-fat distribution changes with age, and hormone transitions are part of that biology.

In women, the menopausal transition is frequently accompanied by a shift toward greater abdominal and visceral fat accumulation. Aging, activity, sleep, energy balance and loss of muscle also contribute, so it is too simplistic to attribute every change in body composition to estrogen alone. Even so, longitudinal and imaging studies support a meaningful relationship between menopause and central fat redistribution.

Menopausal hormone therapy can influence body composition in some women and may attenuate some of the increase in central adiposity associated with menopause. We do not prescribe hormone therapy as a visceral-fat treatment or as a weight-loss medication. Hormone therapy should be considered for appropriate clinical indications, with the expected benefits, risks and individual medical history considered together.

Men have a related but different pattern. Lower testosterone is frequently associated with obesity, declining muscle mass, insulin resistance and greater visceral adiposity. Testosterone therapy in appropriately selected hypogonadal men can improve aspects of body composition, but again, reducing visceral fat is not by itself an indication for testosterone treatment.

Hormone treatment works best when it is part of a larger strategy that also addresses muscle, exercise, nutrition, sleep and metabolic health.

How We Approach Reducing Visceral Fat

There is no single visceral-fat protocol because the reasons someone accumulates abdominal fat differ. Someone becoming insulin resistant during menopause may need a different plan from a sedentary man losing muscle in his sixties, or from a patient with obesity, sleep apnea and fatty liver disease.

Exercise

Exercise is one of the most consistently supported interventions for reducing visceral adiposity. Aerobic exercise, higher-intensity aerobic work, interval training and combined aerobic and resistance programs have all demonstrated benefit.

Resistance training remains important even when another form of exercise produces a greater reduction in VAT in a particular study. In longevity medicine, the goal is not to reduce fat at the expense of muscle. Skeletal muscle supports glucose disposal, strength, physical function and long-term metabolic reserve.

Nutrition

Nutrition should support the metabolic problem actually present. For many people this means improving food quality, increasing minimally processed foods and fiber, reducing excess refined carbohydrates and added sugars, consuming adequate protein and creating an appropriate energy deficit when fat loss is needed.

At HormoneSynergy®, we generally favor a plant- and protein-forward Mediterranean pattern rather than treating one diet label as universally correct. Protein needs vary, but approximately 1.2 to 1.6 grams per kilogram of body weight per day is often considered when preserving or building lean mass is an important goal.

Sleep and Recovery

Persistent sleep deprivation, untreated sleep apnea, circadian disruption and chronic stress can make metabolic improvement considerably more difficult. These factors can influence appetite, insulin sensitivity, activity, recovery and the hormonal signals involved in energy regulation.

For someone exercising and eating reasonably well but continuing to accumulate abdominal fat, sleep and recovery deserve a serious evaluation rather than another increasingly restrictive diet.

Insulin Resistance and Cardiometabolic Risk

Visceral fat and insulin resistance commonly reinforce one another. This is why we may evaluate fasting insulin, glucose, HOMA-IR, hemoglobin A1c, triglycerides, ApoB, liver markers, blood pressure and related cardiovascular factors when the VAT measurement is elevated.

See our guide to HOMA-IR and Insulin Resistance for a closer look at how metabolic dysfunction can develop while fasting glucose still appears normal.

GLP-1 Therapy When Appropriate

GLP-1 based medications can produce substantial reductions in total and visceral fat in appropriately selected patients. The body-composition analysis from the STEP 1 semaglutide trial is useful because it also illustrates why we follow muscle during medical weight loss.

In that DEXA subgroup, semaglutide treatment was associated with an approximately 19.3% reduction in total fat mass and a 27.4% reduction in regional visceral fat, while measured lean body mass also declined by approximately 9.7%. Because fat fell substantially more than lean tissue, overall body composition improved, but the loss of lean mass reinforces the need to pay attention to protein intake, resistance training and physical function during significant weight loss.

The endpoint of GLP-1 treatment should not simply be a lower number on a scale. We want to know what tissue was lost and what was preserved.

How HormoneSynergy® Uses DEXA and Visceral Fat

We use visceral-fat measurement as one component of preventive longevity medicine rather than treating it as an isolated score.

Some people simply want an objective body-composition baseline. HormoneSynergy® offers stand-alone Hologic® DEXA and SECA testing in Lake Oswego for both established patients and non-patients. The current complete DEXA and SECA package is $200 and includes bone density, whole-body composition, visceral-fat analysis, lean-mass assessment and printed reports. A separate physician interpretation with Dr. Kathryn Retzler is available for an additional fee.

Other people want to understand why their body composition is changing and how it connects with insulin resistance, cardiovascular risk, menopause, testosterone, thyroid function, sleep, cognition or other aspects of aging. For those patients, DEXA is included within the broader HormoneSynergy® Optimal Aging Assessment, where body composition can be interpreted alongside advanced laboratory testing, cardiovascular assessment, hormone evaluation, cognitive testing and a detailed physician consultation.

The usefulness of the DEXA scan is not simply that it produces another number. It allows us to see whether the body is moving toward more muscle and less metabolically unfavorable fat, or in the opposite direction, and then place that information alongside the rest of the person's physiology.

Selected References

1. Katzmarzyk PT, Greenway FL, Heymsfield SB, Bouchard C. Clinical utility and reproducibility of visceral adipose tissue measurements derived from dual-energy X-ray absorptiometry in White and African American adults. Obesity. 2013. PMID: 23794256.
2. Goldberg EK, Fung EB. Precision of the Hologic DXA in the assessment of visceral adipose tissue. Journal of Clinical Densitometry. 2020. PMID: 30992223.
3. MRI-based validation of abdominal adipose tissue measurements from DXA in postmenopausal women. PMID: 34404568.
4. Visceral Adiposity Thresholds for Cardiovascular Risk Stratification: A Simplified Biomarker-Driven Model. 2025. PMID: 40825749.
5. Chen X, et al. Effects of various exercise types on visceral adipose tissue in individuals with overweight and obesity: a systematic review and network meta-analysis of 84 randomized controlled trials. Obesity Reviews. 2024. PMID: 38031812.
6. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. PMCID: PMC8089287.
7. Menopause and Body Composition: A Complex Field. 2025. PMID: 40489975.

Frequently Asked Questions

Can you have high visceral fat with a normal BMI?

Yes. BMI does not distinguish visceral fat from subcutaneous fat or skeletal muscle. Some people with a normal body weight can still have an unfavorable amount of visceral fat, particularly when muscle mass is relatively low.

Is DEXA accurate for measuring visceral fat?

Modern DEXA systems provide validated imaging-based estimates of visceral adipose tissue that correlate well with CT and MRI in many populations. CT and MRI remain the reference methods for detailed anatomical quantification. DEXA is attractive clinically because it can assess visceral fat together with lean mass, total fat, regional fat distribution and bone density using a low-radiation examination.

What visceral-fat number should I aim for?

There is no single universal VAT target that applies across every scanner, software system, age, sex and patient population. We prefer to interpret the measurement within the reference system being used, alongside metabolic risk markers and previous measurements from the same scanner.

How often should visceral fat be measured?

The appropriate interval depends on why the test is being performed. For many people, repeating a DEXA after approximately 6 to 12 months provides a useful longer-term body-composition comparison. During active weight loss or body recomposition, SECA analysis can be used more frequently between DEXA scans to follow lean mass and fat-mass trends.

Does menopause cause visceral-fat gain?

The menopause transition is associated with a tendency toward greater central and visceral fat accumulation, although aging, activity, nutrition, sleep, genetics and muscle loss also contribute. Hormone status should therefore be considered as part of the larger metabolic picture rather than assumed to be the sole cause.

Can hormone therapy reduce visceral fat?

Hormone therapy can influence body composition in appropriately selected women and men, but visceral-fat reduction alone is not an indication for estrogen or testosterone therapy. Hormone treatment should be based on symptoms, clinical history, laboratory findings, expected benefits and individual risks.

This article is for educational purposes and is not a substitute for individualized medical evaluation, diagnosis or treatment.